Larvol Delta - Abcentra-Announces-First-Patients-Dosed-with-Orticumab-in-Clinical-Trial-Evaluating-Blockade-of-Oxidized-LDL-in-Psoriasis-with-Elevated-Cardiometabolic-Risk

orticumab (BI 204) - Roche, Abcentra

https://www.prnewswire.com/news-releases/abcentra-announces-first-patients-dosed-with-orticumab-in-clinical-trial-evaluating-blockade-of-oxidized-ldl-in-psoriasis-with-elevated-cardiometabolic-risk-301347684.html

Aug 4, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next